Cross-Sector entity
BMO Capital Markets is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. Each carries 2 original sources on average.
2 verified stories tracked
Last mentioned: Aug 16, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
BMO Capital Markets is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. The clearest coverage concentration is earnings: 1 of 2 stories, with the rest divided among 1 other category. Each carries 2 original sources on average. We currently track 2 Cross-Sector stories that mention Konstantinos Xynos, all published on August 16, 2026.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Konstantinos Xynos. Shared-story counts are live from our verified record — not editorial picks.
Earnings release
Replimune Group reported ($0.72) EPS, missing the ($0.69) Zacks consensus by $0.03. Stock opened at $14.97, down $0.22.
Insider sales
CEO Sushil Patel sold 39,341 shares at $12.97 and insider Konstantinos Xynos sold 11,447 shares at $12.97, both to cover tax withholding obligations.
Wedbush upgrade
Wedbush upgraded Replimune Group from neutral to outperform and set a $12.00 price target.
Leerink upgrade
Leerink Partners upgraded Replimune Group from market perform to outperform and raised its price target from $11.00 to $17.00.
BMO upgrade
BMO Capital Markets raised Replimune Group from underperform to outperform with a $16.00 price target.
Wall Street Zen upgrade
Wall Street Zen upgraded Replimune Group from strong sell to sell.
Replimune missed consensus EPS by $0.03 but held near its 52-week high at $14.97. Insider sales totaling over $650,000 were tax-related, while analyst targets now range up to $17, creating a gap between the $11.86 average target and the stock price.
Replimune reported ($0.72) EPS, missing by $0.03, but for biotech investors the quarter is a side note to pipeline catalysts and analyst upgrades. Insider sales were tax-related, and recent price targets of $16 to $17 suggest confidence in the oncolytic immunotherapy platform.
Source: tickerreport.com · themarketsdaily.com
